Driven by excellence, focused on strategies for the longer term.

This is the crux of who we are. It is an articulation of precision in purpose, from the Firm’s beginnings to where we are today. Our collective eye is unerringly trained on tomorrow.

Deep sectoral expertise across services and industries.

Our insistence on strategic advisory exacts an in-depth understanding of and involvement with our clients’ businesses and industries. We engage not just individual businesses, but also contribute to the country’s legal and regulatory frameworks.

Personal commitment supported by experience and grit.

We commit early. We pull together internally for greater support. Every effort is sincere, every individual deeply dedicated to their task, their role, to the Firm.

Our undertakings for long-term impact are an organic extension of our purpose.

They are to employ our deep knowledge of the law beyond the business, the transaction, the deal. To use the opportunities and skills we possess, to reflect on the culture we’re creating. Individually and collectively, these are our efforts to help shape the thinking of our future generations, and arm them with strategies for true, sustainable growth.

Knowledge-sharing is intrinsic to equity and inclusivity.

This is a repository of thought leadership, deep insights and strong viewpoints, legal and other news and events and how they impact the industry and our clients.

Relevance is critical to growth. It necessitates a firm that is dynamic and responsive.

Amplifying intrinsic talent, sharpening skills, expanding knowledge, is vital to leading. It defines every aspect of how our firm functions and transacts. This is how we create new benchmarks and set industry standards.

  • Connect
Sep 30, 2020

MCA Amends Scope of CSR Activities in light of COVID-19 Pandemic

MCA, by a Notification dated August 24, 2020, has amended Rule 2(1)(e) of the Companies (Corporate Social Responsibility) Rules, 2014 (‘CSR Rules’). Rule 2(1)(e) of the CSR Rules provides that the corporate social responsibility (‘CSR’) policy of a company should relate to activities undertaken by the company as specified in Schedule VII and are required to exclude activities which are undertaken by the company in the normal course of its business. Pursuant to the amendment, the MCA has introduced a carve out to this requirement whereby any company engaged in research and development activity of new vaccines, drugs and medical devices in its normal course of business may undertake, for CSR purposes, research and development activity of new vaccines, drugs and medical devices related to COVID-19 for the financial years 2020-21, 2021-22 and 2022-23 subject to certain specified conditions.

TAGS

SHARE

Subscribe

DISCLAIMER

These are the views and opinions of the author(s) and do not necessarily reflect the views of the Firm. This article is intended for general information only and does not constitute legal or other advice and you acknowledge that there is no relationship (implied, legal or fiduciary) between you and the author/AZB. AZB does not claim that the article's content or information is accurate, correct or complete, and disclaims all liability for any loss or damage caused through error or omission.

RELATED READING

Inter Alia

Opening of Additional Current Account for Export Proceeds for Category-I AD Banks

Jan 23, 2024 | Private Equity & Venture Capital Regulatory & Securities
Inter Alia

SC Held That Mere Contemplation of Urgent Relief Should Not Be a Guise to Bypass Statutory Pre-Litigation Mediation

Jan 23, 2024 | Dispute Resolution
Inter Alia

Foreign Exchange Management (Manner of Receipt and Payment) Regulations, 2023

Jan 23, 2024 | Financial Services Private Equity & Venture Capital Regulatory & Securities